(Guangzhou, China, November 14, 2022) Beside the Rhine River in Düsseldorf, Pluslife is showcasing its most recent point-of-care diagnostic innovations in the MEDICA 2022. Pluslife’s product demonstration is held in Booth No.1H39-7 from Nov 14 to 17 and the most recent developed Eight-Channel POC Molecular Analyzer, HPV tests, and STD tests will be available for inquiries.  

When the global COVID-19 pandemic still maintains high diagnosing demands to healthcare systems, seasonal epidemics often create more difficulties for medical organizations simultaneously from time to time. Pluslife is well acknowledged of this dilemma and aims to provide a comprehensive solution to solve such issues. Either the new Eight-Channel POC Molecular Analyzer or the Mini Dock Integrated Nucleic Acid Testing Device is capable to diagnose different pathogens with a single test, with the application of new test kits such as the HPV 16/18/46 Test Card, the STD NG/UU Test Card, the STD CT/NG/UU Test Card, and the SARS-CoV-2/Flu A/Flu B Test Card,. This comprehensive solution can help medical departments to become better organized and effectively differentiate medical admission in a short period.

During the exhibition, pavilion visitors are attracted by the profound capabilities of Pluslife’s Eight-Channel POC Molecular Analyzer with its flexibility, efficiency, and accuracy. The analyzer contains multiple sample slots, which is able to inspect up to 8 samples at the same time, and the portable feature and the clinical proven test performances are all taken into account with its compact and stackable design.

As one of the top-notch molecular POCT solution developers, Pluslife is excited to present its expanded types of POC analyzers in its first attendance of MEDICA that points the way to encouraging possibilities of cooperations, which will implement effectual solutions to the increasing demands of molecular POC diagnostics under new public health challenges.